Order Article Reprints

Han X, Wei M, Zheng X, Wan P, Tang J, Zhang L, Zhang S, Zhou H, Lu J, Zhou L, et al. Immunogenicity, Safety, and Immune Persistence of One Dose of SARS-CoV-2 Recombinant Adenovirus Type-5 Vectored Vaccine in Children and Adolescents Aged 6–17 Years: An Immunobridging Trial. Vaccines. 2024; 12(6):683. https://doi.org/10.3390/vaccines12060683

Han, Xu, Mingwei Wei, Xiuyu Zheng, Peng Wan, Jie Tang, Lu Zhang, Shupeng Zhang, Hanchi Zhou, Jiayu Lu, Li Zhou, and et al. 2024. "Immunogenicity, Safety, and Immune Persistence of One Dose of SARS-CoV-2 Recombinant Adenovirus Type-5 Vectored Vaccine in Children and Adolescents Aged 6–17 Years: An Immunobridging Trial" Vaccines 12, no. 6: 683. https://doi.org/10.3390/vaccines12060683

Han, X., Wei, M., Zheng, X., Wan, P., Tang, J., Zhang, L., Zhang, S., Zhou, H., Lu, J., Zhou, L., Zhu, Y., Li, J., & Zhu, F. (2024). Immunogenicity, Safety, and Immune Persistence of One Dose of SARS-CoV-2 Recombinant Adenovirus Type-5 Vectored Vaccine in Children and Adolescents Aged 6–17 Years: An Immunobridging Trial. Vaccines, 12(6), 683. https://doi.org/10.3390/vaccines12060683